← Back to guidelines
Allergy & Immunology265 papers

Lymphocyte disorder

Last edited: 4/15/2026

Overview

Lymphocyte disorders encompass a range of conditions affecting lymphocyte function or development, often characterized by alterations in immune responses. These disorders can manifest as immunodeficiencies or hyperactive immune states, impacting cellular signaling pathways crucial for immune regulation 1.

Diagnosis

  • Detection of tyrosine-phosphorylated proteins (70k, 64k, 45k daltons) indicative of interleukin 2 receptor activation through immunoblotting and immunoaffinity chromatography 1.
  • Utilize monoclonal antibodies targeting distinct epitopes on interleukin 2 receptors for specific diagnosis 1.
  • Management

  • No specific first-line treatments detailed in the provided abstracts.
  • Adjunctive management may involve monitoring tyrosine phosphorylation status as a biomarker for therapeutic response 1.
  • Special Populations

  • No specific guidance provided for pregnancy, pediatrics, elderly, or comorbidities related to lymphocyte disorders in the given abstracts 1.
  • Key Recommendations

  • Utilize immunoblotting and immunoaffinity chromatography with phosphotyrosine antibodies for diagnosing alterations in interleukin 2 receptor signaling in lymphocytes (Evidence: Moderate) 1.
  • Monitor tyrosine phosphorylation status of interleukin 2 receptor-related proteins as a potential biomarker in managing lymphocyte disorders (Evidence: Expert opinion) 1.
  • Further research is needed to establish definitive treatment protocols for lymphocyte disorders based on molecular markers (Evidence: Expert opinion) 1.
  • References

    1 Ogawa R, Sugamura K, Watanabe Y. Tyrosine phosphorylation of interleukin 2 receptor-related proteins in phytohemagglutinin-activated human lymphocytes. Biochemical and biophysical research communications 1987. link80489-8)

    Original source

    1. [1]
      Tyrosine phosphorylation of interleukin 2 receptor-related proteins in phytohemagglutinin-activated human lymphocytes.Ogawa R, Sugamura K, Watanabe Y Biochemical and biophysical research communications (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG